Michael G. Kelly

Michael G. Kelly

Chief Tech/Sci/R&D Officer presso CureDuchenne

Health Technology
Consumer Services
Finance

Profilo

Michael G.
Kelly
is currently the Director at Trinds LLC since 2017 and the Chief Scientific Officer at CureDuchenne since 2011.
Previously, he worked as the President, Chief Executive Officer & Director at MyoTherix, Inc. He was also the Research Director at Amgen, Inc. from 1999 to 2000.
Additionally, he worked as a Director at NeoGenesis Pharmaceuticals, Inc. and as the Senior Vice President-Research & Development at Renovis, Inc. Dr. Kelly holds a doctorate degree from The University of Southampton and an undergraduate degree from the University of Ulster.

Posizioni attive di Michael G. Kelly

SocietàPosizioneInizio
Chief Tech/Sci/R&D Officer 13/12/2011
Director/Board Member 01/11/2017
Tutte le posizioni attive di Michael G. Kelly

Precedenti posizioni note di Michael G. Kelly

SocietàPosizioneFine
AMGEN INC. Chief Tech/Sci/R&D Officer 01/01/2000
Chief Tech/Sci/R&D Officer -
Director/Board Member -
Chief Executive Officer -
Vedi nel dettaglio l'esperienza di Michael G. Kelly

Formazione di Michael G. Kelly

The University of Southampton Doctorate Degree
University of Ulster Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Michael G. Kelly

Relazioni

57

Relazioni di 1° grado

8

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa1
AMGEN INC.

Health Technology

Aziende private5

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Michael G. Kelly